Aptose's Tuspetinib Triple Drug Therapy Featured at 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Population

Aptose Biosciences Inc. (TSE: APS - Get Free Report) (NASDAQ: APTO) crossed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of C$1.89 and traded as high as C$2.32. Aptose Biosciences shares last traded at C$2.32, with a volume of 4,636 shares. Analyst Ratings Changes Separately, Alliance

SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on April 15, 2025, KPMG LLP, the current independent registered public accounting firm of the Company (the “KPMG”), informed the Company that it will not stand for re-appointment for the Company's 2025 annual audit. The Company anticipates that KPMG will continue to review its quarterly interim financial results through the first two fiscal quarters of 2025.

SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that the Aptose management team will participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference being held in Toronto, May 5-6, 2025. Dr. William G.

Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial Results to Date Highlight TUS Potential as an Ideal Third Drug to Include in AML Triplet Therapy Aptose Signs Debt Conversion Agreement with Hanmi SAN DIEGO and TORONTO, March 28, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the year ended December 31, 2024, and provided a corporate update.   "During 2024 and into 2025, we continue to advance our lead investigational drug tuspetinib in combination with venetoclax (VEN) and azacitidine (AZA) for frontline treatment of newly diagnosed acute myeloid leukemia (AML),” said William G.

SAN DIEGO and TORONTO, March 17, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that it received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that it is in compliance with Nasdaq's minimum bid price requirement. On March 14, 2025, Nasdaq confirmed that, for ten consecutive business days, the closing bid price of the Company's common shares has been $1.00 per share or greater.

On Thursday, Aptose Biosciences Inc. APTO announced that the Cohort Safety Review Committee monitoring Phase 1/2 TUSCANY trial of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine (TUS+VEN+AZA triplet) has approved escalating from 40 mg TUS to 80 mg TUS based on its favorable review of data from the first four patients in the trial.

Aptose Announces Positive Clinical Safety Review and Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib

SAN DIEGO and TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today announced that its board of directors (the “Board”) has approved, subject to required regulatory and stock exchange approvals, a plan to consolidate all of its outstanding common shares (the “Common Shares”) on the basis of 1 Common Share for every 30 Common Shares currently outstanding (the "Reverse Share Split"). The Company expects the Reverse Share Split to restore compliance with the minimum bid price requirement set out in Nasdaq Listing Rule 5550(a)(2) and to ensure the Company continues to have access to a wide range of investors.

SAN DIEGO and TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today announced it has entered into a common share purchase agreement and registration rights agreement with an institutional investor. The Committed Equity Facility agreement provides Aptose the right, in its sole option and discretion without obligation, to sell and issue up to $25 million of its common shares (the “Common Shares”) over the course of 24 months to the Investor, subject to certain conditions being met, and subject to certain limitations and conditions imposed by the Nasdaq Capital Market (“Nasdaq”), the U.S. Securities and Exchange Commission (the “SEC”) and other regulators.